Symbols / BDSX
BDSX Chart
About
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 103.28M |
| Enterprise Value | 161.37M | Income | -39.54M | Sales | 80.17M |
| Book/sh | -0.22 | Cash/sh | 2.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 273 | IPO | — |
| P/E | — | Forward P/E | -58.68 | PEG | — |
| P/S | 1.29 | P/B | -59.77 | P/C | — |
| EV/EBITDA | -6.06 | EV/Sales | 2.01 | Quick Ratio | 1.61 |
| Current Ratio | 1.84 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.23 | EPS next Y | -0.22 | EPS Growth | — |
| Revenue Growth | 19.90% | Earnings | 2026-02-26 | ROA | -21.12% |
| ROE | -3.03% | ROIC | — | Gross Margin | 79.82% |
| Oper. Margin | -32.36% | Profit Margin | -49.31% | Shs Outstand | 7.96M |
| Shs Float | 3.03M | Short Float | 5.74% | Short Ratio | 0.07 |
| Short Interest | — | 52W High | 19.14 | 52W Low | 3.44 |
| Beta | 0.68 | Avg Volume | 1.46M | Volume | 42.63K |
| Target Price | $32.50 | Recom | Strong_buy | Prev Close | $13.02 |
| Price | $12.91 | Change | -0.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$32.50
Mean price target
2. Current target
$12.79
Latest analyst target
3. DCF / Fair value
$-35.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.79
Low
$20.00
High
$40.00
Mean
$32.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2025-09-19 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2025-05-21 | main | Scotiabank | Sector Outperform → Sector Outperform | $2 |
| 2025-05-14 | main | Craig-Hallum | Buy → Buy | $2 |
| 2025-05-14 | main | Lake Street | Buy → Buy | $2 |
| 2025-05-14 | main | Canaccord Genuity | Buy → Buy | $2 |
| 2025-05-14 | down | William Blair | Outperform → Market Perform | — |
| 2025-04-29 | main | Canaccord Genuity | Buy → Buy | $3 |
| 2024-09-16 | init | Scotiabank | — → Sector Outperform | $3 |
| 2024-07-26 | init | Craig-Hallum | — → Buy | $3 |
| 2024-05-13 | init | TD Cowen | — → Buy | $3 |
| 2024-05-03 | init | Lake Street | — → Buy | $3 |
| 2024-03-04 | reit | Canaccord Genuity | Buy → Buy | $4 |
| 2023-12-07 | reit | Canaccord Genuity | Buy → Buy | $4 |
| 2022-05-12 | main | Morgan Stanley | — → Equal-Weight | $5 |
| 2022-04-20 | init | Cowen & Co. | — → Outperform | — |
| 2021-11-17 | down | Morgan Stanley | Overweight → Equal-Weight | $11 |
| 2021-05-12 | main | Morgan Stanley | — → Overweight | $23 |
| 2021-03-18 | main | Morgan Stanley | — → Overweight | $25 |
| 2021-02-02 | main | Canaccord Genuity | — → Buy | $31 |
- Cowie, Biodesix CFO, sells $6834 in BDSX stock - Investing.com ue, 24 Feb 2026 02
- Biodesix management to speak at TD Cowen and Barclays events - Stock Titan ue, 24 Feb 2026 11
- Insider Sale: Chief Development Officer of $BDSX Sells 556 Shares - Quiver Quantitative ue, 24 Feb 2026 01
- Insider Selling: Biodesix (NASDAQ:BDSX) CEO Sells 1,490 Shares of Stock - MarketBeat ue, 24 Feb 2026 02
- Biodesix officer Pestano sells $7103 in BDSX stock - Investing.com ue, 24 Feb 2026 02
- Telemark Asset Management LLC Trims Position in Biodesix, Inc. $BDSX - MarketBeat Sun, 22 Feb 2026 13
- O’Kane, Biodesix CCO, sells $6834 in BDSX stock By Investing.com - Investing.com South Africa ue, 24 Feb 2026 02
- Insider Sale: Chief Commercial Officer of $BDSX Sells 584 Shares - Quiver Quantitative Wed, 11 Feb 2026 08
- Biodesix (BDSX) Projected to Post Earnings on Thursday - MarketBeat hu, 19 Feb 2026 09
- $BDSX stock is up 27% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- $BDSX stock is down 15% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Sep 2025 07
- Biodesix, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call Details - Quiver Quantitative hu, 12 Feb 2026 11
- Canaccord Genuity Group Reiterates Buy Rating for Biodesix (NASDAQ:BDSX) - MarketBeat ue, 17 Feb 2026 16
- Biodesix director Schuler buys $1.1m+ in BDSX stock By Investing.com - Investing.com Nigeria ue, 27 Jan 2026 08
- Biodesix (NYSE: BDSX) to validate ddPLEX ESR1 assay; IVD filings and CLIA-CAP service - Stock Titan Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1490 | 19036.0 | — | Sale at price 12.78 per share. | HUTTON SCOTT | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
| 1 | 535 | 6835.0 | — | Sale at price 12.78 per share. | O'KANE KIERAN | Officer | — | 2026-02-23 00:00:00 | D |
| 2 | 535 | 6835.0 | — | Sale at price 12.78 per share. | COWIE ROBIN HARPER | Chief Financial Officer | — | 2026-02-23 00:00:00 | D |
| 3 | 556 | 7103.0 | — | Sale at price 12.78 per share. | PESTANO GARY ANTHONY | Officer | — | 2026-02-23 00:00:00 | D |
| 4 | 211 | 2696.0 | — | Sale at price 12.78 per share. | VAZQUEZ CHRISTOPHER | Officer | — | 2026-02-23 00:00:00 | D |
| 5 | 4844 | nan | — | — | HUTTON SCOTT | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
| 6 | 1469 | nan | — | — | O'KANE KIERAN | Officer | — | 2026-02-20 00:00:00 | D |
| 7 | 1469 | nan | — | — | COWIE ROBIN HARPER | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 8 | 1528 | nan | — | — | PESTANO GARY ANTHONY | Officer | — | 2026-02-20 00:00:00 | D |
| 9 | 563 | nan | — | — | VAZQUEZ CHRISTOPHER | Officer | — | 2026-02-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -28.73M | -35.78M | -44.55M | -36.15M |
| TotalUnusualItems | -486.00K | -1.32M | -6.98M | 676.00K |
| TotalUnusualItemsExcludingGoodwill | -486.00K | -1.32M | -6.98M | 676.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -42.93M | -52.15M | -65.45M | -43.16M |
| ReconciledDepreciation | 5.46M | 5.51M | 5.84M | 3.18M |
| ReconciledCostOfRevenue | 15.57M | 13.01M | 14.15M | 30.52M |
| EBITDA | -29.22M | -37.10M | -51.53M | -35.47M |
| EBIT | -34.67M | -42.61M | -57.38M | -38.65M |
| NetInterestIncome | -8.26M | -9.54M | -8.07M | -4.51M |
| InterestExpense | 8.26M | 9.54M | 8.07M | 4.51M |
| NormalizedIncome | -42.45M | -50.83M | -58.47M | -43.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -42.93M | -52.15M | -65.45M | -43.16M |
| TotalExpenses | 105.58M | 90.39M | 88.72M | 93.82M |
| TotalOperatingIncomeAsReported | -34.50M | -41.34M | -50.59M | -40.94M |
| DilutedAverageShares | 6.48M | 4.11M | 2.11M | 1.37M |
| BasicAverageShares | 6.48M | 4.11M | 2.11M | 1.37M |
| DilutedEPS | -6.60 | -12.80 | -31.00 | -31.60 |
| BasicEPS | -6.60 | -12.80 | -31.00 | -31.60 |
| DilutedNIAvailtoComStockholders | -42.93M | -52.15M | -65.45M | -43.16M |
| NetIncomeCommonStockholders | -42.93M | -52.15M | -65.45M | -43.16M |
| NetIncome | -42.93M | -52.15M | -65.45M | -43.16M |
| NetIncomeIncludingNoncontrollingInterests | -42.93M | -52.15M | -65.45M | -43.16M |
| NetIncomeContinuousOperations | -42.93M | -52.15M | -65.45M | -43.16M |
| PretaxIncome | -42.93M | -52.15M | -65.45M | -43.16M |
| OtherIncomeExpense | -413.00K | -1.31M | -6.87M | 667.00K |
| OtherNonOperatingIncomeExpenses | 73.00K | 6.00K | 109.00K | -9.00K |
| SpecialIncomeCharges | -486.00K | -44.00K | -7.06M | 676.00K |
| OtherSpecialCharges | 248.00K | 6.98M | -2.30M | |
| ImpairmentOfCapitalAssets | 238.00K | 44.00K | 81.00K | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 1.62M | ||
| GainOnSaleOfSecurity | -1.27M | 84.00K | ||
| NetNonOperatingInterestIncomeExpense | -8.26M | -9.54M | -8.07M | -4.51M |
| InterestExpenseNonOperating | 8.26M | 9.54M | 8.07M | 4.51M |
| OperatingIncome | -34.26M | -41.30M | -50.51M | -39.32M |
| OperatingExpense | 90.01M | 77.38M | 74.56M | 63.31M |
| ResearchAndDevelopment | 9.56M | 9.99M | 13.10M | 12.79M |
| SellingGeneralAndAdministration | 80.45M | 67.39M | 61.46M | 50.52M |
| SellingAndMarketingExpense | 61.46M | 50.52M | ||
| GrossProfit | 55.75M | 36.08M | 24.06M | 23.99M |
| CostOfRevenue | 15.57M | 13.01M | 14.15M | 30.52M |
| TotalRevenue | 71.32M | 49.09M | 38.21M | 54.51M |
| OperatingRevenue | 71.32M | 49.09M | 38.21M | 54.51M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 7.27M | 4.81M | 3.88M | 1.54M |
| ShareIssued | 7.27M | 4.81M | 3.88M | 1.54M |
| NetDebt | 10.18M | 8.99M | ||
| TotalDebt | 61.98M | 60.69M | 31.85M | 10.01M |
| TangibleBookValue | -29.00K | -18.36M | -4.22M | -6.92M |
| InvestedCapital | 57.30M | 39.86M | 45.66M | 29.74M |
| WorkingCapital | 25.17M | 6.27M | 30.50M | 14.65M |
| NetTangibleAssets | -29.00K | -18.36M | -4.22M | -6.92M |
| CapitalLeaseObligations | 25.55M | 25.41M | 6.80M | 0.00 |
| CommonStockEquity | 20.88M | 4.58M | 20.61M | 19.73M |
| TotalCapitalization | 57.28M | 39.80M | 45.61M | 29.72M |
| TotalEquityGrossMinorityInterest | 20.88M | 4.58M | 20.61M | 19.73M |
| StockholdersEquity | 20.88M | 4.58M | 20.61M | 19.73M |
| RetainedEarnings | -462.50M | -419.57M | -367.42M | -301.97M |
| AdditionalPaidInCapital | 483.23M | 424.05M | 387.95M | 321.67M |
| CapitalStock | 145.00K | 96.00K | 78.00K | 31.00K |
| CommonStock | 145.00K | 96.00K | 78.00K | 31.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 76.37M | 94.52M | 72.30M | 56.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 62.05M | 61.10M | 49.46M | 27.41M |
| OtherNonCurrentLiabilities | 815.00K | 712.00K | 19.20M | 17.42M |
| LongTermDebtAndCapitalLeaseObligation | 61.24M | 60.39M | 30.26M | 9.99M |
| LongTermCapitalLeaseObligation | 24.83M | 25.16M | 5.25M | 0.00 |
| LongTermDebt | 36.41M | 35.23M | 25.00M | 9.99M |
| CurrentLiabilities | 14.32M | 33.42M | 22.84M | 28.96M |
| OtherCurrentLiabilities | 641.00K | 22.15M | 10.38M | 17.76M |
| CurrentDeferredLiabilities | 678.00K | 324.00K | 962.00K | 1.85M |
| CurrentDeferredRevenue | 678.00K | 324.00K | 962.00K | 1.85M |
| CurrentDebtAndCapitalLeaseObligation | 740.00K | 303.00K | 1.59M | 19.00K |
| CurrentCapitalLeaseObligation | 719.00K | 252.00K | 1.54M | 0.00 |
| CurrentDebt | 21.00K | 51.00K | 49.00K | 19.00K |
| OtherCurrentBorrowings | 21.00K | 51.00K | 49.00K | 19.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.77M | 3.85M | 4.67M | 4.03M |
| PayablesAndAccruedExpenses | 5.49M | 6.78M | 5.23M | 5.30M |
| CurrentAccruedExpenses | 3.29M | 3.85M | 3.55M | 3.64M |
| Payables | 2.19M | 2.93M | 1.69M | 1.66M |
| AccountsPayable | 2.19M | 2.93M | 1.69M | 1.66M |
| TotalAssets | 97.24M | 99.10M | 92.91M | 76.10M |
| TotalNonCurrentAssets | 57.76M | 59.41M | 39.57M | 32.48M |
| OtherNonCurrentAssets | 7.26M | 6.86M | 5.92M | 1.66M |
| GoodwillAndOtherIntangibleAssets | 20.91M | 22.94M | 24.83M | 26.65M |
| OtherIntangibleAssets | 5.87M | 7.91M | 9.80M | 11.62M |
| Goodwill | 15.03M | 15.03M | 15.03M | 15.03M |
| NetPPE | 29.59M | 29.61M | 8.82M | 4.18M |
| AccumulatedDepreciation | -9.13M | -5.61M | -7.02M | -6.75M |
| GrossPPE | 38.73M | 35.22M | 15.84M | 10.93M |
| Leases | 28.19M | 24.71M | 2.37M | 2.34M |
| ConstructionInProgress | 89.00K | 0.00 | 2.95M | 17.00K |
| OtherProperties | 7.62M | 7.83M | 9.01M | 6.78M |
| MachineryFurnitureEquipment | 2.83M | 2.68M | 1.52M | 1.79M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 39.48M | 39.68M | 53.33M | 43.61M |
| OtherCurrentAssets | 4.64M | 5.72M | 5.18M | 7.25M |
| Receivables | 8.60M | 7.68M | 5.07M | 3.66M |
| AccountsReceivable | 8.60M | 7.68M | 5.07M | 3.66M |
| AllowanceForDoubtfulAccountsReceivable | -481.00K | -65.00K | -118.00K | -158.00K |
| GrossAccountsReceivable | 9.08M | 7.74M | 5.18M | 3.81M |
| CashCashEquivalentsAndShortTermInvestments | 26.25M | 26.28M | 43.09M | 32.71M |
| CashAndCashEquivalents | 26.25M | 26.28M | 43.09M | 32.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -52.09M | -45.93M | -48.51M | -30.77M |
| RepaymentOfDebt | -51.00K | -49.00K | -28.60M | -45.43M |
| IssuanceOfDebt | 0.00 | 10.00M | 45.10M | 30.08M |
| IssuanceOfCapitalStock | 55.62M | 28.13M | 59.54M | 16.34M |
| CapitalExpenditure | -3.44M | -23.06M | -3.53M | -2.55M |
| InterestPaidSupplementalData | 7.02M | 3.99M | 1.01M | 1.68M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 26.33M | 26.37M | 43.17M | 32.80M |
| BeginningCashPosition | 26.37M | 43.17M | 32.80M | 62.31M |
| ChangesInCash | -39.00K | -16.80M | 10.38M | -29.51M |
| FinancingCashFlow | 52.05M | 29.13M | 58.88M | 1.26M |
| CashFlowFromContinuingFinancingActivities | 52.05M | 29.13M | 58.88M | 1.26M |
| NetOtherFinancingCharges | -4.17M | -9.68M | -17.78M | -828.00K |
| ProceedsFromStockOptionExercised | 650.00K | 734.00K | 624.00K | 1.10M |
| NetCommonStockIssuance | 55.62M | 28.13M | 59.54M | 16.34M |
| CommonStockIssuance | 55.62M | 28.13M | 59.54M | 16.34M |
| NetIssuancePaymentsOfDebt | -51.00K | 9.95M | 16.50M | -15.35M |
| NetLongTermDebtIssuance | -51.00K | 9.95M | 16.50M | -15.35M |
| LongTermDebtPayments | -51.00K | -49.00K | -28.60M | -45.43M |
| LongTermDebtIssuance | 0.00 | 10.00M | 45.10M | 30.08M |
| InvestingCashFlow | -3.44M | -23.06M | -3.53M | -2.55M |
| CashFlowFromContinuingInvestingActivities | -3.44M | -23.06M | -3.53M | -2.55M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -210.00K | -143.00K | -236.00K | -306.00K |
| PurchaseOfIntangibles | -210.00K | -143.00K | -236.00K | -306.00K |
| NetPPEPurchaseAndSale | -3.23M | -22.92M | -3.30M | -2.24M |
| PurchaseOfPPE | -3.23M | -22.92M | -3.30M | -2.24M |
| OperatingCashFlow | -48.65M | -22.87M | -44.97M | -28.22M |
| CashFlowFromContinuingOperatingActivities | -48.65M | -22.87M | -44.97M | -28.22M |
| ChangeInWorkingCapital | -21.67M | -7.02M | -6.82M | 4.59M |
| ChangeInOtherWorkingCapital | 248.00K | -755.00K | -1.21M | -1.68M |
| ChangeInOtherCurrentLiabilities | -22.53M | -3.00M | -937.00K | 875.00K |
| ChangeInOtherCurrentAssets | 784.00K | 938.00K | -2.39M | 1.37M |
| ChangeInPayablesAndAccruedExpense | 1.64M | 513.00K | -773.00K | -7.42M |
| ChangeInReceivables | -1.81M | -4.72M | -1.50M | 11.45M |
| ChangesInAccountReceivables | -1.81M | -4.72M | -1.50M | 11.45M |
| OtherNonCashItems | 2.48M | 23.60M | 8.41M | 4.33M |
| StockBasedCompensation | 6.64M | 5.37M | 5.96M | 4.94M |
| ProvisionandWriteOffofAssets | 887.00K | 497.00K | 93.00K | 193.00K |
| AssetImpairmentCharge | 238.00K | 44.00K | 81.00K | 0.00 |
| DepreciationAmortizationDepletion | 5.46M | 5.51M | 5.84M | 3.18M |
| DepreciationAndAmortization | 5.46M | 5.51M | 5.84M | 3.18M |
| Depreciation | 5.46M | 5.51M | 5.84M | 3.18M |
| OperatingGainsLosses | 248.00K | 1.27M | 6.90M | -2.30M |
| GainLossOnInvestmentSecurities | 1.27M | -84.00K | ||
| NetIncomeFromContinuingOperations | -42.93M | -52.15M | -65.45M | -43.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BDSX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|